TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

CALDOLOR

IBUPROFEN Cyclooxygenase Inhibitors
Immunology Approved 2009-06-11
5
Indications
--
Phase 3 Trials
1
Priority Reviews
16
Years on Market

Details

Status
Prescription
First Approved
2009-06-11
Routes
INTRAVENOUS
Dosage Forms
SOLUTION

Companies

Active Ingredient: IBUPROFEN

CALDOLOR Approval History

Loading approval history...

What CALDOLOR Treats

2 indications

CALDOLOR is approved for 2 conditions since its original approval in 2009. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Pain
  • Fever
Source: FDA Label

CALDOLOR Boxed Warning

RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. ( 5.1 ) CALDOLOR is contraindicated in the setting of c...

Drugs Similar to CALDOLOR

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

IMMPHENTIV
PHENYLEPHRINE HYDROCHLORIDE
2 shared
Hikma
Shared indications:
PainFever
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE
2 shared
GENUS
Shared indications:
PainFever
PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
PHENYLEPHRINE HYDROCHLORIDE
2 shared
Dr. Reddy's
Shared indications:
PainFever
ACUVAIL
KETOROLAC TROMETHAMINE
1 shared
AbbVie
Shared indications:
Pain
ALLZITAL
ACETAMINOPHEN
1 shared
PHARMOBEDIENT
Shared indications:
Fever
ANAPROX DS
NAPROXEN SODIUM
1 shared
ATNAHS PHARMA US
Shared indications:
Fever
ANEXSIA 5/325
ACETAMINOPHEN
1 shared
SPECGX LLC
Shared indications:
Fever
ANEXSIA 7.5/325
ACETAMINOPHEN
1 shared
SPECGX LLC
Shared indications:
Fever
BELBUCA
BUPRENORPHINE HYDROCHLORIDE
1 shared
BDSI
Shared indications:
Pain
BUPRENORPHINE
BUPRENORPHINE
1 shared
WATSON LABS TEVA
Shared indications:
Pain
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
ASPIRIN
1 shared
STEVENS J
Shared indications:
Pain
BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE
1 shared
Hikma
Shared indications:
Pain
BUTORPHANOL TARTRATE PRESERVATIVE FREE
BUTORPHANOL TARTRATE
1 shared
Pfizer
Shared indications:
Pain
BUTRANS
BUPRENORPHINE
1 shared
PURDUE PHARMA LP
Shared indications:
Pain
BYQLOVI
CLOBETASOL PROPIONATE
1 shared
HARROW EYE
Shared indications:
Pain
CATAFLAM
DICLOFENAC POTASSIUM
1 shared
AMICI PHARMA
Shared indications:
Pain
COMBOGESIC IV
ACETAMINOPHEN
1 shared
Hikma
Shared indications:
Pain
DICLOFENAC POTASSIUM
DICLOFENAC POTASSIUM
1 shared
INGENUS PHARMS LLC
Shared indications:
Pain
DIFLUNISAL
DIFLUNISAL
1 shared
Teva
Shared indications:
Pain
DIFLUPREDNATE
DIFLUPREDNATE
1 shared
Cipla
Shared indications:
Pain
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CALDOLOR FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

CALDOLOR is indicated in adults and pediatric patients aged 3 months and older for the: management of mild to moderate pain and the management of moderate to severe pain as an adjunct to opioid analgesics reduction of fever CALDOLOR is a nonsteroidal anti-inflammatory drug indicated in adults and pediatric patients aged 3 months and older for the: Management of mild to moderate pain and the management of moderate to severe pain as an adjunct to opioid analgesics Reduction of fever

⚠️ BOXED WARNING

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombo...

CALDOLOR Patents & Exclusivity

Latest Patent: Mar 2032
Exclusivity: May 2026

Patents (42 active)

US9072661 Expires Mar 16, 2032
US9072710 Expires Mar 16, 2032
US11806400 Expires Mar 16, 2032
US9012508 Expires Sep 14, 2030
US9114068 Expires Sep 30, 2029
US8735452 Expires Sep 30, 2029
US9649284 Expires Sep 30, 2029
US8871810 Expires Sep 30, 2029
US9295639 Expires Sep 30, 2029
US9138404 Expires Sep 30, 2029
+ 32 more patents

Exclusivity

NPP Until May 2026
NPP Until May 2026
NPP Until May 2026
NPP Until May 2026
NPP Until May 2026
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.